logo

For the Inventor, By the Inventor

Somerville, MA, United States of America

Partha Pratim Nag

This inventor holds 11 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: The Broad Institute, Inc., Dana-Farber-Cancer Institute Inc., The General Hospital Corporation. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Partha Pratim Nag. Retrieved from https://idiyas.com/inventor/partha-pratim-nag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 100.0


Average Co-Inventor Count = 9.8

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:

goldMedal11 out of 486 
 
The Broad Institute, Inc.
 patents
silverMedal6 out of 1,268 
 
Dana-Farber-Cancer Institute Inc.
 patents
bronzeMedal5 out of 3,073 
 
The General Hospital Corporation
 patents
4. 3 out of 8,586 
 
Massachusetts Institute of Technology
 patents
5. 1 out of 538 
 
Beth Israel Deaconess Medical Center, Inc.
 patents
6. 1 out of 3,075 
 
Harvard College
 patents
7. 1 out of 1,208 
 
Scripps Research Institute
 patents
8. 1 out of 1,428 
 
The Brigham and Women's Hospital, Inc.
 patents
9. 1 out of 318 
 
Whitehead Institute for Biomedical Research
 patents
where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 12419885 - Kinase inhibitors and methods of use thereof (2025-09-23),
2. 12152008 - Cyclopentaimidazolones for the treatment of cancer (2024-11-26),
3. 11247970 - Selective inhibition of gluconeogenic activity (2022-02-15),
4. 11052080 - Kinase inhibitors and methods of use thereof (2021-07-06),
5. 10301294 - Compounds for the treatment of tuberculosis (2019-05-28),
6. 10137122 - Kinase inhibitors and methods of use thereof (2018-11-27),
7. 10064853 - Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase (2018-09-04),
8. 9951055 - Thiazole-based inhibitors of scavenger receptor BI (2018-04-24),
9. 9884851 - Heterocycle-bisamide inhibitors of scavenger receptor BI (2018-02-06),
10. 9738610 - Indazole derivatives and uses thereof (2017-08-22),
11. 9096594 - Kinase inhibitors and methods of use thereof (2015-08-04),

Title: Partha Pratim Nag: Innovator in Kinase Inhibitors and Cancer Treatment

Introduction

Partha Pratim Nag is a prominent inventor based in Somerville, MA (US), known for his significant contributions to the field of pharmaceutical sciences. He holds a total of 11 patents, focusing primarily on kinase inhibitors and their applications in treating various diseases.

Latest Patents

Among his latest patents, Nag has developed compounds that serve as kinase inhibitors, particularly targeting GSK3 and CK1 activities. These compounds are crucial for treating kinase-mediated disorders, including neurological diseases, psychiatric disorders, metabolic disorders, and cancer. Another notable patent involves cyclopentaimidazolones, which are designed for the treatment of proliferative diseases, specifically pancreatic cancer. These compounds can be formulated into pharmaceutical compositions for effective treatment and prophylaxis.

Career Highlights

Throughout his career, Partha Pratim Nag has worked with esteemed organizations such as the Broad Institute, Inc. and Dana-Farber Cancer Institute. His work has significantly advanced the understanding and treatment of various diseases, particularly in the realm of cancer research.

Collaborations

Nag has collaborated with notable colleagues, including Benito Munoz and Sivaraman Dandapani, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

Partha Pratim Nag's innovative work in kinase inhibitors and cancer treatment exemplifies the impact of dedicated research in pharmaceutical sciences. His contributions continue to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…